Anatomical, functional improvements seen after switch to ranibizumab in persistent DME unresponsive to bevacizumab

Posted on

Anatomical and functional improvements after treatment with ranibizumab were seen in patients with persistent diabetic macular edema (DME) who were unresponsive to bevacizumab, however patients treated with aflibercept only showed an anatomical improvement, according to a study.

In this single-center retrospective comparative study, 40 patients (56 eyes) with DME unresponsive to intravitreal bevacizumab were switched to ranibizumab (n = 33 eyes) or aflibercept (n = 23 eyes). Best-corrected visual acuity and central foveal thickness were recorded before the switch and again 4 months after.

Both groups had a significant median decrease in central foveal thickness decrease. A significant best-corrected visual acuity gain was seen in patients treated with ranibizumab. No pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept.

Pessoa B, Malheiro L, Carneiro I, et al. Intravitreal ranibizumab or aflibercept after bevacizumab in diabetic macular edema: Exploratory retrospective analysis. Clin Ophthalmol. 2021;15: 253-260.

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021